Bedside myocardial perfusion assessment with contrast echocardiography

Critical Care

Volumn 20, Issue 1, 2016, Pages

  Orde, Sam ^a   McLean, Anthony ^a,b  

^a NEPEAN HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUNEX; ECHO CONTRAST MEDIUM; ECHOVIST; PERFLUTREN; SHU 508; SONOVUE;

ACUTE CORONARY SYNDROME; CONTRAST ECHOCARDIOGRAPHY; CONTRAST ENHANCEMENT; DRUG TARGETING; HEART MUSCLE PERFUSION; HUMAN; MYOCARDIAL PERFUSION IMAGING; NONHUMAN; OSCILLATION; PATIENT SAFETY; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; ULTRASOUND; CRITICAL ILLNESS; ECHOCARDIOGRAPHY; INTENSIVE CARE UNIT; POINT OF CARE SYSTEM; PROCEDURES;

CRITICAL ILLNESS; ECHOCARDIOGRAPHY; HUMANS; INTENSIVE CARE UNITS; MYOCARDIAL PERFUSION IMAGING; POINT-OF-CARE SYSTEMS;

EID: 84962868898     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-016-1215-7     Document Type: Review

References (33)

1. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53:802-10.
2. Gramiak R, Shah PM, Kramer DH. Ultrasound cardiography: contrast studies in anatomy and function. Radiology. 1969;92:939-48.
3. Keller MW, Feinstein SB, Watson DD. Successful left ventricular opacification following peripheral venous injection of sonicated contrast agent: an experimental evaluation. Am Heart J. 1987;114:570-5.
4. Feinstein SB, Cheirif J, Ten Cate FJ, et al. Safety and efficacy of a new transpulmonary ultrasound contrast agent: initial multicenter clinical results. J Am Coll Cardiol. 1990;16:316-24.
5. Lindner JR, Dent JM, Moos SP, et al. Enhancement of left ventricular cavity opacification by harmonic imaging after venous injection of Albunex. Am J Cardiol. 1997;79:1657-62.
6. Postema M, van Wamel A, Ten Cate FJ, de Jong N. High-speed photography during ultrasound illustrates potential therapeutic applications of microbubbles. Med Phys. 2005;32:3707-11.
7. Keller MW, Segal SS, Kaul S, Duling B. The behavior of sonicated albumin microbubbles within the microcirculation: a basis for their use during myocardial contrast echocardiography. Circ Res. 1989;65:458-67.
8. Platts DG, Fraser JF. Contrast echocardiography in critical care: echoes of the future? A review of the role of microsphere contrast echocardiography. Crit Care Resusc. 2011;13:44-55.
9. Seol S-H, Lindner JR. A primer on the methods and applications for contrast echocardiography in clinical imaging. J Cardiovasc Ultrasound. 2014;22:101-10.
10. Pathan F, Marwick TH. Myocardial perfusion imaging using contrast echocardiography. Prog Cardiovasc Dis. 2015;57:632-43.
11. Seol S-H, Davidson BP, Belcik JT, et al. Real-time contrast ultrasound muscle perfusion imaging with intermediate-power imaging coupled with acoustically durable microbubbles. J Am Soc Echocardiogr. 2015;28:718-726.e2.
12. Jayaweera AR, Edwards N, Glasheen WP, et al. In vivo myocardial kinetics of air-filled albumin microbubbles during myocardial contrast echocardiography. Comparison with radiolabeled red blood cells. Circ Res. 1994;74:1157-65.
13. Wei K, Jayaweera AR, Firoozan S, et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation. 1998;97:473-83.
14. Vogel R, Indermühle A, Reinhardt J, et al. The quantification of absolute myocardial perfusion in humans by contrast echocardiography: algorithm and validation. J Am Coll Cardiol. 2005;45:754-62.
15. Main ML, Hibberd MG, Ryan A, et al. Acute mortality in critically ill patients undergoing echocardiography with or without an ultrasound contrast agent. JACC Cardiovasc Imaging. 2014;7:40-8.
16. Abdelmoneim SS, Bernier M, Scott CG, et al. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study. Circ Cardiovasc Imaging. 2010;3:240-8.
17. Wei K, Mulvagh SL, Carson L, et al. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses. J Am Soc Echocardiogr. 2008;21:1202-6.
18. Putrino A, Platts DG. Contrast echocardiography in acutely unwell patients. J Am Soc Echocardiogr. 2015;28:844.
19. U.S. Food and Drug Administration. Postmarket Drug Safety Information for Patients and Providers. Information for Healthcare Professionals: Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection). 2008. Update FDA alert. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm125574.htm. Accessed Oct 2015.
20. Mulvagh SL, Rakowski H, Vannan MA, et al. American society of echocardiography consensus statement on the clinical applications of ultrasonic contrast agents in echocardiography. J Am Soc Echocardiogr. 2008;21:1179-201.
21. Parker JM, Weller MW, Feinstein LM, et al. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts. Am J Cardiol. 2013;112:1039-45.
22. Lim W, Whitlock R, Khera V, et al. Etiology of troponin elevation in critically ill patients. J Crit Care. 2010;25:322-8.
23. Orde SR, Pulido JN, Masaki M, et al. Outcome prediction in sepsis: speckle tracking echocardiography based assessment of myocardial function. Crit Care. 2014;18:R149.
24. Orde SR, Huang SJ, McLean AS. 2015 ASE 26th Annual Scientific Sessions. Raised Troponin in the ICU: can real-time myocardial contrast echocardiography improve recognition of acute ischaemia in the critically ill? JASE. 2015;28:B2-B134. abst.
25. Senior R, Becher H, Monaghan M, et al. Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography. Eur J Echocardiogr. 2009;10:194-212.
26. Dijkmans PA, Senior R, Becher H, et al. Myocardial contrast echocardiography evolving as a clinically feasible technique for accurate, rapid, and safe assessment of myocardial perfusion: the evidence so far. J Am Coll Cardiol. 2006;48:2168-77.
27. Senior R, Janardhanan R, Jeetley P, Burden L. Myocardial contrast echocardiography for distinguishing ischemic from nonischemic first-onset acute heart failure: insights into the mechanism of acute heart failure. Circulation. 2005;112:1587-93.
28. Abdelmoneim SS, Mankad SV, Bernier M, et al. Microvascular function in Takotsubo cardiomyopathy with contrast echocardiography: prospective evaluation and review of literature. J Am Soc Echocardiogr. 2009;22:1249-55.
29. Ait-Oufella H, Bourcier S, Lehoux S, Guidet B. Microcirculatory disorders during septic shock. Curr Opin Crit Care. 2015;21:271-5.
30. Linka AZ, Sklenar J, Wei K, et al. Assessment of transmural distribution of myocardial perfusion with contrast echocardiography. Circulation. 1998;98:1912-20.
31. Schneider AG, Goodwin MD, Schelleman A, et al. Contrast-enhanced ultrasound to evaluate changes in renal cortical perfusion around cardiac surgery: a pilot study. Crit Care. 2013;17:R138.
32. Schneider AG, Goodwin MD, Schelleman A, et al. Contrast-enhanced ultrasonography to evaluate changes in renal cortical microcirculation induced by noradrenaline: a pilot study. Crit Care. 2014;18:653.
33. Bhattacharyya S, Senior R. The current state of myocardial contrast echocardiography: what can we read between the lines? Reply. Eur Heart J Cardiovasc Imaging. 2014;15:351-2.